Navigation Links
Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
Date:9/25/2007

matrix for the drug delivery, oncology, and dermatology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its first partnership is with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets. In addition, the company has received FDA approval for two products: Cumulase(R) and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter Healthcare Corporation. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the development of Chemophase and the release of interim data related to current clinical trials) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact Investor Relations Contact<
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Charlene Vernak, RPh, of ... , recently was awarded the George Roentsch Scholarship ... received the award in Houston ... scholarship is awarded annually to an independent pharmacist and ... of George Roentsch , a well-known pharmacist in ...
(Date:10/22/2014)... October 22, 2014 A new ... Market (Product type, Form, End user, Application and Geography) ... Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - ... market. Based on key trends tracked, it is anticipated ... $7.9 billion by 2020, registering a CAGR of 6.2% ...
(Date:10/22/2014)... ST. LOUIS , Oct. 21, 2014 /PRNewswire-USNewswire/ ... are often subtle or unnoticed, but new technology, ... patient outcomes and leading to earlier detection of ... now affects 29 million Americans. If left untreated, ... or even blindness. Recently, optometric ...
Breaking Medicine Technology:PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3
... , , Trial taking place ... Ky., July 24 Michael (Mike) Jones has become the world,s first ... infusion on July 17 marks the world,s first phase-one FDA-approved clinical trial ... is being conducted by a team of University of Louisville physicians at ...
... , WISCONSIN RAPIDS, Wis., July 23 ... Riverview became the first medical facility in the world to ... within Riverview Hospital, Wisconsin Rapids, the UW Cancer Center Riverview ... FDA-cleared Axxent(R) Electronic Brachytherapy System from Xoft, Inc. Electronic Brachytherapy, ...
Cached Medicine Technology:World's First Cardiac Adult Stem Cell Patient Receives Infusion 2First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 2First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 3
(Date:10/22/2014)... RESTON, Va. (PRWEB) October 22, 2014 ... Healthcare Innovation , which is dedicated to distribute ... efficiency of healthcare delivery worldwide announced the development ... in which patients expect when receiving healthcare. These ... definition for patient-centered care: “providing care that is ...
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
(Date:10/22/2014)... Weight Your Body’s Way , In a world where a ... certainly can be difficult to choose the right weight loss ... doing it the healthy way? Set aside the fads and ... exercise regularly, and choose foods with the most nutritional benefits. ... to exercise more and eat less. Despite the number of ...
(Date:10/22/2014)... Prussia, PA (PRWEB) October 22, 2014 ... recognized as an industry leader with over 25 years ... winning team leader in the areas related to EDI, ... Mr. Carlson is an Editorial Advisory Board member for ... Council Educator. Blue Fin Group is a management ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... women undergoing in vitro fertilization (IVF) are only about half ... popular assisted reproduction technique, new research indicates, and the racial ... the study, about 31 percent of white patients became pregnant ... Analyzing more than 4,000 IVF cycles over two years ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
... in the January issue of Health Affairs ... the costly chronic disease that affects nearly 26 million ... Health (RSPH) systematically reviewed the published literature and analyzed ... Program (DPP) trial in real-world settings. Published in 2002, ...
... News) -- A drug commonly used to treat patients with ... older than 40 years who have Down syndrome and Alzheimer,s, ... animal studies of the Alzheimer,s drug, memantine, showed promising results ... with Down syndrome aged 40 and older revealed the opposite, ...
... therapies (NRTs) designed to help people stop smoking, specifically nicotine ... in helping smokers quit long-term, even when combined with smoking ... Harvard School of Public Health (HSPH) and the University of ... in an advance online edition of Tobacco Control ...
... HealthDay Reporter , MONDAY, Jan. 9 (HealthDay News) -- There ... research that finds losing a loved one can increase the ... significant other,s death, heart attack risk was 21 times higher ... 2,000 heart attack patients. And within the first week after ...
... , Every year, Americans drink 13.8 billion gallons of soda, ... mass consumption of sugar that is fueling soaring obesity and ... a group of scientists at the University of California, San ... and Columbia University have analyzed the effect of a nationwide ...
... Maureen Salamon HealthDay Reporter , MONDAY, Jan. 9 ... migraine patients as three types of traditional acupuncture, a new ... four groups at nine Chinese hospitals -- one sham acupuncture ... of researchers, including Dr. Fan-rong Liang at Chengdu University in ...
Cached Medicine News:Health News:Diabetes study shines spotlight on lifestyle interventions 2Health News:Diabetes study shines spotlight on lifestyle interventions 3Health News:Alzheimer's Med Seems Ineffective in Those With Down Syndrome 2Health News:Nicotine replacement therapies may not be effective in helping people quit smoking 2Health News:Grief Is a Real Heartbreaker, Study Finds 2Health News:Grief Is a Real Heartbreaker, Study Finds 3Health News:How many lives could a soda tax save? 2Health News:Power of Acupuncture to Ease Migraines Questioned in Study 2Health News:Power of Acupuncture to Ease Migraines Questioned in Study 3
Hydroview insertion forcep with very thin jaws to allow insertion through tunnel or clear cornea incision. Locking. Made in titanium....
Angled insertion forcep used for the Hydroview lens. Manufactured in titanium....
... This forcep was designed with thinner, ... the Hydroview IOL through a tunnel ... grasp the lens securely, but ... jaws open wide enough to allow ...
Titanium. Forceps designed for insertion of Hydroview foldable intraocular lenses. Unique cross-action design allows for easy insertion of most foldable lens styles....
Medicine Products: